Free  Drugs to avoid in 2026

Marketing Authorisations

Sotatercept (Winrevair°) in pulmonary arterial hypertension

Pegzilarginase (Loargys°) in arginase 1 deficiency

Nusinersen (Spinraza°) or onasemnogene abeparvovec (Zolgensma°) in spinal muscular atrophy before the onset of sym­ptoms

Pembrolizumab (Keytruda°) after surgery, or both before and after surgery, in certain types of lung cancer

Baricitinib (Olumiant°) in juvenile idiopathic arthritis

Enfortumab vedotin (Padcev°) + pembrolizumab (Keytruda°) in unresectable or metastatic urothelial carcinoma

Editors' opinion. Cutting corners

Spesolimab (Spevigo°) in the prevention or treatment of flares of generalised pustular psoriasis

Tenecteplase 5000 unit vials (Metalyse°) in acute ischaemic stroke

Nirsevimab (Beyfortus°) as prophylaxis for certain infants during exposure to their second RSV season

Maralixibat (Livmarli°) in progressive familial intrahepatic cholestasis

Amivantamab (Rybrevant°) in first-line treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations

Amivantamab (Rybrevant°) in second-line treatment for non-small cell lung cancer with EGFR exon 19 or exon 21 mutations

Ebola vaccine rVSV-Zebov (Ervebo°) in children in an outbreak of Ebola virus disease

Adverse Effects

MRNA covid-19 vaccines: a review of adverse effects (continued)

Inset. Pregnancy and mRNA covid-19 vaccines authorised in the European Union (continued)

Anabolic androgenic steroids: cardiac events and venous thromboembolism

Common stem: ­-teplase

Hormonal contraception: deep vein thrombosis

Lithium: renal impairment

Outlook

Free  Towards better patient care: drugs to avoid in 2026

Inset. Main changes in the 2026 update of ­­Prescrire's drugs to avoid

Masthead

Free  Masthead